SCHEMBL4404602

SCHEMBL4404602

CC(C)(C)Cc1cccc(-n2ccnc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.54
CYP3A4 P08684 3/20 0.50
CYP19A1 P11511 2/20 0.46
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
CYP2A6 P11509 1/20 0.46
GLS O94925 2/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
MEN1 O00255 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4475935 0.83 IDO1 (0.55) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL4485099 0.83 IDO1 (0.58) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL9969422 0.81 LMNA (0.58) CYP3A4CYP19A1LMNAMAPTCYP1A2
SCHEMBL1754328 0.80 AOC2 (0.51) MAPT
SCHEMBL3199392 0.80 IDO1 (0.63) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL3211483 0.80 IDO1 (0.58) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL15750592 0.80 IDO1 (0.58) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL29471945 0.80 IDO1 (0.58) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL14489499 0.78 IDO1 (0.75) IDO1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL5316200 0.78 IDO1 (0.53) IDO1CYP3A4CYP19A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 US disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 US disclosed
US-8962642-B2 5-cyano-4- (pyrrolo [2,3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-20140045812-A1 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2014-02-13 US disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045812-A1 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS MAP3K5, CDK5, MAP4K2 IDO1 2191/4885CYP3A4 2072/4885CYP19A1 3372/4885
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK IDO1 940/4885CYP3A4 639/4885CYP19A1 1294/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK IDO1 940/4885CYP3A4 639/4885CYP19A1 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.